- Poster presentation
- Open Access
Ghrelin: an anti-inflammatory theurapeutic agent in septic rats
© Uluçay et al.; licensee BioMed Central Ltd. 2014
Published: 3 December 2014
Sepsis is a life-threatening systemic inflammatory syndrome (SIRS), which affects many organ systems, that leads to hemodynamic changes in the presence of suspected or proven infection, advancing to organ dysfunction and failure [1–3]. In recent studies, 377 out of 100,000 cases of sepsis were observed while $14,600,000,000 has been determined as the average annual hospital costs. Although there are many studies, the molecular mechanism is not yet clearly elucidated [2, 3]. Lipopolysaccharide (LPS) is the lipid molecule which the outer membrane of Gram-negative bacteria used in designing the experimental sepsis model . Ghrelin was discovered in 1999 as a specific ligand for growth hormone secretagogue receptor and then pleiotropic effects such as anti-inflammatory, antioxidant, and so forth were found. Ghrelin was released in many tissues and organs in which there also was its receptor. The liver is an organ which has ghrelin receptors and was affected by sepsis primary [5, 6].
In our study, male Wistar albino rats of average body mass 200 to 250 g were separated into four groups including: Control (n = 10), LPS (E. coli 055:B5, 5 mg/kg, n = 10), ghrelin (10 nmol/kg i.v., n = 10), LPS + ghrelin LPS (5 mg/kg, ghrelin 10 nmol/kg i.v., n = 10). Rats were decapitated 24 hours after first injection. We aimed in this study to investigate effects of ghrelin in sepsis which is created by LPS with sepsis descriptive parameters such as body temperature and leukocyte count with proinflammatory cytokine TNFα and anti-inflammatory cytokines IL-10 by ELISA, and hematoxylin and eosin stain for observed morphological changes.
We think the results of ghrelin may be affected depending on the dose and duration. Also partial healing effects of ghrelin in our results on this topic at the molecular level will contribute to other studies.
- Angus DC, van der Poll T: Severe sepsis and septic shock. N Engl J Med 2013, 369: 2063.View ArticlePubMedGoogle Scholar
- Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G, SCCM/ESICM/ACCP/ATS/SIS: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003, 31: 1250-1256. 10.1097/01.CCM.0000050454.01978.3BView ArticlePubMedGoogle Scholar
- Schorr CA, Zanotti S, Dellinger RP: Severe sepsis and septic shock: management and performance improvement. Virulence 2014, 1: 190-199.View ArticleGoogle Scholar
- Ramachandran G: Gram-positive and gram-negative bacterial toxins in sepsis: a brief review. Virulence 2014, 5: 213-218. 10.4161/viru.27024View ArticlePubMedGoogle Scholar
- Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999, 402: 656-660. 10.1038/45230View ArticlePubMedGoogle Scholar
- Chang L, Zhao J, Yang J, Zhang Z, Du J, Tang C: Therapeutic effects of ghrelin on endotoxic shock in rats. Eur J Pharmacol 2003, 473: 171-176. 10.1016/S0014-2999(03)01972-1View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.